source
- Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trialKallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…
- UniQure’s Huntington’s gene therapy shows reduced benefit in fourth year, but patient remains optimisticUniQure reported new data on its experimental Huntington’s disease gene therapy, AMT-130, in a four‑year follow‑up of 12 patients. The update showed the treatment slowed disease progression by 44%,…